Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Mason

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Journal of Cancer Research and Clinical Oncology|August 10, 2006
What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?Malcolm Mason
European Urology|June 7, 2011
Re: Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation doseMalcolm Mason
European Urology|September 5, 2018
Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate CancerMalcolm Mason
Journal of Endourology|April 13, 2010
Candidate selection for prostate cancer focal therapySamir S Taneja, Malcolm Mason
Clinical Evidence|September 16, 2004
Malignant melanoma (non-metastatic)David Crosby, Thomas Crosby, Malcolm Mason
Clinical Evidence|April 20, 2006
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|November 24, 2004
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|May 4, 2005
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|September 17, 2002
Malignant melanoma: non-metastaticDavid Crosby, Thomas Crosby, Malcolm Mason
Expert Review of Anticancer Therapy|July 3, 2004
ImagingAndrzej Dzik-Jurasz, Malcolm Mason, Harvey Schipper
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Journal of Cancer Research and Clinical Oncology|August 10, 2006
What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?Malcolm Mason
European Urology|June 7, 2011
Re: Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation doseMalcolm Mason
European Urology|September 5, 2018
Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate CancerMalcolm Mason
Journal of Endourology|April 13, 2010
Candidate selection for prostate cancer focal therapySamir S Taneja, Malcolm Mason
Clinical Evidence|September 16, 2004
Malignant melanoma (non-metastatic)David Crosby, Thomas Crosby, Malcolm Mason
Clinical Evidence|April 20, 2006
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|November 24, 2004
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|May 4, 2005
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|September 17, 2002
Malignant melanoma: non-metastaticDavid Crosby, Thomas Crosby, Malcolm Mason
Expert Review of Anticancer Therapy|July 3, 2004
ImagingAndrzej Dzik-Jurasz, Malcolm Mason, Harvey Schipper
Pageof 8